The article informs that Osaka, Japan Takeda Pharmaceutical Co. Ltd. of has acquired Inviragen Inc., biotech company for innovative vaccines and emerging infectious diseases and will also pay 35 million dollars upfront and up to 215 million dollars in clinical and commercial milestones.